Team in Toronto and Winnipeg to Begin Production of Medical Scrubs and Patient Gowns

Part of the Canada Goose Response Program

Canada Goose reports they will begin making scrubs and patient gowns, which are in short supply across the country, and will begin distributing them to hospitals next week.

To help address the urgent need facing healthcare workers and patients across the country, Canada Goose has committed to producing medical gear at two of its manufacturing facilities, starting in Toronto and Winnipeg, with the opportunity to extend production across additional facilities as needed. With production set to begin early next week, approximately 50 employees per facility will work to manufacture the gear and have an initial goal of producing 10,000 units.

“Across Canada, there are people risking their lives every day on the frontlines of COVID-19 in healthcare facilities, and they need help. Now is the time to put our manufacturing resources and capabilities to work for the greater good,” said Dani Reiss, President & CEO, Canada Goose. “Our employees are ready, willing and able to help, and that’s what we’re doing. It’s the Canadian thing to do.”

The company is working closely with federal, provincial and local health authorities and will follow the recommended protocols to ensure a safe work environment for employees, including implementing social distancing protocols, limiting the number of employees located within specific spaces, and increasing sanitation measures within facilities to ensure the health and safety of team members.

Canada Goose Response Program COVID-19 Initiatives to date:

  • Production of Personal Protective Equipment: Beginning week of March 30th, Canada Goose will manufacture scrubs for healthcare workers as well as patient gowns. The gear will be donated locally at no cost, with the goal of providing as much equipment as possible to those in need.

  • Canada Goose Employee Support Fund: On March 17th the Canada Goose Employee Support fund was established for employees who are impacted by store and manufacturing closures but are not eligible for government assistance. In a letter to Canada Goose employees, Dani Reiss announced that he will forego his salary for at least the next three months, which will be used for the Employee Support Fund. 

  • Wuhan Charity Donation: On February 6th Canada Goose announced a RMB1 million donation to the Wuhan Charity Federation to help fight the COVID-19 outbreak. The Wuhan Charity Federation is a non-profit organization designated by the Wuhan City Epidemic Prevention and Control Headquarters to receive donations for relief efforts.

Other device and supply news can be found here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version